Please assess the completion status of the following clinical trial:

Trial Title: A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of skin, gut and/or liver steroid-refractory GVHD by clinical assessment of treating physician following allogeneic HCT. Patients who fail to respond to steroids by 7 days are considered steroid-refractory~2. Previously-treated with any conditioning regimen and any GVHD immune suppression prophylaxis and formulation of steroids, except as noted in Exclusion Criteria #2.~3. AbGn-168H (neihulizumab) therapy can begin not more than 14 days after diagnosis of aGvHD~4. Karnofsky Performance Status (KPS) \> 50%~5. No evidence of HCT graft failure or multi-organ failure~6. Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~1. Uncontrolled infections not responsive to antimicrobial therapy requiring intensive critical care~2. Progressive malignant disease, including post-transplant lymphoproliferative disease unresponsive to therapy~3. Treatment with investigational GVHD prophylactic agents (eg, CCR5 inhibitors; lenalidomide; and/or bortezomib) within the 7 days prior to the 1st dose of neihulizumab~4. Treatment with other investigational agents within the prior 7 days prior to the 1st dose of AbGn-168H (neihulizumab)~5. CMV PCR \> 500 copies/mL or evidence of end-organ damage due to CMV~6. Pregnant or nursing~7. HIV positivity (NOTE: patients positive for hepatitis B or hepatitis C are not excluded, and may be evaluated on a case-by-case basis)~8. Renal clearance CCR \< 40 mL/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AbGn-168H (Type: EXPERIMENTAL): AbGn-168H will be administered once weekly for four weeks via intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).